Management of dementia with a cerebrovascular component

被引:21
作者
Bocti, Christian [1 ]
Black, Sandra
Frank, Chris
机构
[1] Univ Montreal, Dept Med, Div Neurol, Montreal, PQ H3C 3J7, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Neurol, Toronto, ON, Canada
[3] Queens Univ Providence, Dept Med, Program Care Elderly, Kingston, ON, Canada
基金
加拿大健康研究院;
关键词
vascular dementia; vascular cognitive impairment; Alzheimer's disease; guidelines; prevention; therapy;
D O I
10.1016/j.jalz.2007.07.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cerebrovascular disease (CVD) has been reconceptualized as an important factor in cognitive decline and dementia. The concept of vascular cognitive impairment (VCI) has been introduced to capture the whole spectrum of cognitive decline associated with CVD, and to emphasize the possibility of early intervention on vascular risk factors. Methods: Intervention studies in prevention and symptomatic therapy of dementia associated with CVD are reviewed. Results: We present recommendations based on the review of current literature. There is some evidence that treating hypertension can prevent cognitive decline. Galantamine has shown some benefit in the symptomatic treatment of possible Alzheimer's disease with CVD and donepezil has shown some benefits in vascular dementia. Other pharmacologic interventions lack sufficient empirical support. Conclusions: A more pro-active stance towards cognitive decline of vascular etiology is warranted, with some evidence supporting both prevention and symptomatic therapy. (c) 2007 The Alzheimer's Association. All rights reserved.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 54 条
[1]  
[Anonymous], 2000, COCHRANE DATABASE SY
[2]  
[Anonymous], 2002, CALAMUS RENASCENS
[3]  
[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
[4]   NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia [J].
Ballard, CG ;
Burton, EJ ;
Barber, R ;
Stephens, S ;
Kenny, RA ;
Kalaria, RN ;
O'Brien, JT .
NEUROLOGY, 2004, 63 (06) :983-988
[5]   Efficacy and tolerability of donepezil in vascular dementia -: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial [J].
Black, S ;
Román, GC ;
Geldmacher, DS ;
Salloway, S ;
Hecker, J ;
Burns, A ;
Perdomo, C ;
Kumar, D ;
Pratt, R .
STROKE, 2003, 34 (10) :2323-2330
[6]   A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia [J].
Bocti, C ;
Swartz, RH ;
Gao, FQ ;
Sahlas, DJ ;
Behl, P ;
Black, SE .
STROKE, 2005, 36 (10) :2126-2131
[7]   Conceptual background to vascular cognitive impairment [J].
Bowler, JV ;
Steenhuis, R ;
Hachinski, V .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1999, 13 :S30-S37
[8]  
Clare L., 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003260
[9]   Vascular factors in dementia: an overview [J].
DeCarli, C .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 226 (1-2) :19-23
[10]  
Di Bari M, 2001, AM J EPIDEMIOL, V153, P72, DOI 10.1093/aje/153.1.72